BIOLASE to Participate at the Benchmark Company Discovery One on One Investor Conference on November 18, 2020
BIOLASE, Inc. (NASDAQ: BIOL), a leader in dental lasers, will take part in the Benchmark Company Discovery One on One Investor Conference on November 18, 2020. CEO Todd Norbe and CFO John Beaver will engage in virtual meetings with institutional investors. This event highlights BIOLASE's strong commitment to advancing dental and medical laser technologies, evidenced by their proprietary systems featuring 259 patented and 41 patent-pending technologies. To date, BIOLASE has sold over 41,500 lasers across more than 80 countries, focusing on delivering superior outcomes with less pain for patients.
- None.
- None.
FOOTHILL RANCH, Calif., Nov. 13, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been invited to participate in the Benchmark Company Discovery One on One Investor Conference on November 18, 2020. President and CEO Todd Norbe and Executive Vice President, CFO and COO John Beaver will hold virtual meetings with institutional investors throughout the day.
For additional information or to schedule a virtual meeting with BIOLASE, please contact your Benchmark representative, or the EVC Group, LLC, BIOLASE's investor relations firm.
About BIOLASE, Inc.
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 259 patented and 41 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 41,500 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
View original content to download multimedia:http://www.prnewswire.com/news-releases/biolase-to-participate-at-the-benchmark-company-discovery-one-on-one-investor-conference-on-november-18-2020-301172969.html
SOURCE BIOLASE, Inc.
FAQ
What is BIOLASE participating in on November 18, 2020?
Who will represent BIOLASE at the conference?
What does BIOLASE specialize in?
How many laser systems has BIOLASE sold?
What technological innovations does BIOLASE offer?
